telmisartan has been researched along with Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Benard, F; Bennewith, KL; Cederberg, RA; Colpo, N; Firmino, NS; Franks, SE; Lee, CM; Lin, KS; Pan, J; Wadsworth, BJ | 1 |
| Hosoda, A; Kohno, T; Masamichi, S; Matsumoto, Y; Toriyama, Y; Tsuji, T; Yoshida, Y | 1 |
| Dudás, J; Ganswindt, U; Riechelmann, H; Skvortsov, S; Skvortsova, II; Steinbichler, TB | 1 |
| Barrios, V; Escobar, C | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PH; Fryer, RM; Gintant, GA; Larson, KJ; Noonan, WT; Segreti, JA; Tapang, P; Widomski, DL | 1 |
| Debanne, SM; Fang, JC; Rowland, DY; Simon, DI; Sipahi, I | 1 |
| Chang, CH; Lai, MS; Lin, JW; Wu, LC | 1 |
| Nuzum, DS; Olin, JL; Veverka, A | 1 |
7 review(s) available for telmisartan and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Therapy resistance mediated by cancer stem cells.
Topics: ATP-Binding Cassette Transporters; Chemoradiotherapy; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Neoplastic Stem Cells; Radiation Tolerance; Telmisartan | 2018 |
An evaluation of the latest evidence relating to renin-angiotensin system inhibitors.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Fumarates; Humans; Imidazoles; Meta-Analysis as Topic; Neoplasms; Oxadiazoles; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Telmisartan; Tetrazoles | 2013 |
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Telmisartan | 2010 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Control Studies; Double-Blind Method; Humans; Hypertension; Irbesartan; Losartan; Neoplasms; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Control Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Incidence; Logistic Models; Losartan; Male; Middle Aged; Neoplasms; Odds Ratio; Publication Bias; Risk Assessment; Risk Factors; Taiwan; Telmisartan; Tetrazoles | 2011 |
Risk of cancer associated with the use of angiotensin II-receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Male; Meta-Analysis as Topic; Neoplasms; Risk Assessment; Telmisartan | 2011 |
3 other study(ies) available for telmisartan and Neoplasms
| Article | Year |
|---|---|
Angiotensin II type 1 receptor blocker telmisartan inhibits the development of transient hypoxia and improves tumour response to radiation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; Collagen Type I; Fluorescent Dyes; Humans; Losartan; Mice; Neoplasms; Pentoxifylline; Positron-Emission Tomography; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Telmisartan; Tumor Hypoxia; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Topics: Acute Kidney Injury; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blood Pressure; Blood Urea Nitrogen; Calcium Channel Blockers; Cisplatin; Creatinine; Disease Models, Animal; Drug Synergism; Fibrosis; Humans; Injections, Intraperitoneal; Kidney; Male; Mice; Neoplasms; Severity of Illness Index; Telmisartan | 2020 |
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enalapril; Humans; Imidazoles; Indazoles; Lisinopril; Male; Mice; Mice, SCID; Neoplasms; Nifedipine; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Ramipril; Rats; Rats, Sprague-Dawley; Telmisartan; Thiophenes; Xenograft Model Antitumor Assays | 2009 |